Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplied by Immunine binds to activated factor X on phospholipid surfaces, forming the intrinsic tenase complex that converts factor X to Xa. This re‑establishes the intrinsic pathway of the coagulation cascade, leading to thrombin generation and formation of a stable fibrin clot.

The dose of Immunine is individualized by the prescribing clinician based on the patient’s current factor IX activity level, body weight, severity of bleeding, and the clinical situation (e.g., prophylaxis, surgery). Exact dosing regimens are set by the healthcare professional and are not standardized.

Safety data for Immunine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is only considered when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and should be decided by the treating physician.

To order Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any required import documentation.

Immunine is a recombinant human factor IX concentrate, offering a high purity profile and viral inactivation steps comparable to other modern factor IX products. Compared with plasma‑derived concentrates, it eliminates the risk of donor‑derived pathogens and typically provides consistent potency, though clinical choice depends on individual patient needs and physician preference.

Immunine must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to the manufacturer’s guidance.

Immunine is supplied as an injectable solution for intravenous use. It is administered by a qualified healthcare professional through a peripheral or central IV line, following aseptic technique. The infusion rate and volume are determined by the prescriber based on the calculated dose and patient tolerance.

The most serious risks include development of neutralizing antibodies (inhibitors) that reduce efficacy, severe allergic reactions such as anaphylaxis, and thromboembolic events like deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for any signs of these complications during and after infusion.

Immunine should not be used in individuals with a known hypersensitivity to human coagulation factor IX or any component of the formulation. Caution is also advised for patients with a history of inhibitor development, uncontrolled thrombosis, or those receiving concurrent therapies that markedly increase clotting risk.